ARMP Secures FDA Fast Track for AP-SA02, Advances Phase 3 S. aureus Bacteremia Study, $26.2M DoD Award, Potential Accelerated Approval Pathway
Armata Pharmaceuticals, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $7.80
-17% in 7d after detection
Post-detection moves
1h
—
1d
-9.3%
3d
-1.6%
7d
-17%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS